Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2025-04-10 Major Shareholding Noti…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a regulatory filing from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a 'flaggningsmeddelande' (flagging notification). It details a change in shareholding by Redmile Group, LLC in Oncopeptides AB, specifically noting a sale of shares that crossed a 5% threshold. This is a classic major shareholding notification.
2025-04-10 Swedish
Director's Dealing 2025
Director's Dealing Classification · 1% confidence The document details a change in shareholding ('Innehavare', 'Transaktionen', 'Andel') for Oncopeptides AB, specifically reporting the number of shares and voting rights held after a transaction ('Efter transaktionen'). The structure, focusing on 'Antal aktier' (Number of shares) and 'Andel' (Percentage holding), is characteristic of insider trading or major shareholder notifications. Comparing this to the definitions, 'Director's Dealing' (DIRS) covers personal share transactions by directors, and 'Major Shareholding Notification' (MRQ) covers changes in significant share ownership levels (crossing thresholds). Since the document explicitly details the resulting share count and percentage holding after a 'Köp' (Buy) transaction, it most closely aligns with a notification regarding a change in significant share ownership, which falls under the Major Shareholding Notification (MRQ) category, or potentially DIRS if the holder is a director. Given the focus on the resulting percentage (6.42053%) and the structure resembling a regulatory filing about ownership thresholds, MRQ is the most appropriate fit, although DIRS is also plausible if the holder is an insider. However, MRQ specifically covers notifications of changes in significant share ownership levels crossing thresholds, which is what this data represents.
2025-03-03 Swedish
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated February 28, 2025, announcing a change in the total number of shares and votes following the issuance of new C-shares as part of incentive programs. This directly relates to changes in the company's capital structure and share count. This fits the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. Although it mentions the AGM decision authorizing the issuance, the core content is the resulting share count update, not the AGM materials themselves (AGM-R) or a general financing update (CAP). It is a specific notification about share issuance.
2025-02-28 Swedish
Number of shares and votes in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release dated February 28, 2025, announcing a change in the total number of shares and votes due to the issuance of new class C shares related to incentive programs authorized by the AGM. This announcement details a change in the company's capital structure (share count and share capital increase). This fits the definition of 'Capital/Financing Update' (CAP) as it directly relates to capital structure changes and share issuance. Although it involves shares, it is not a report of the company buying back/selling its own shares (POS) but rather an administrative update following a prior authorization. It is not a comprehensive financial report (10-K or IR) nor a general regulatory filing (RNS). Given the specific nature of announcing changes in the number of shares and capital, CAP is the most appropriate classification.
2025-02-28 English
Correction: Issue and re-purchase of class C shares for shareholder program
Capital/Financing Update Classification · 1% confidence The document announces a resolution by the Board of Directors to issue and immediately re-purchase class C shares as part of incentive programs (LTIPs and SHP). This action directly relates to the company's capital structure, specifically involving the issuance and subsequent repurchase of shares, which falls under financing activities or capital structure changes. The most fitting category is 'Capital/Financing Update' (CAP). Although it involves shares, it is a specific transaction related to employee/board compensation plans rather than a general share issue (SHA) or a buyback program announcement (POS), but the core action is a capital structure adjustment via share issuance/repurchase for incentive purposes. Given the context of issuing and re-purchasing shares related to incentive programs, CAP is the best fit, as it describes a financing/capital structure event. The document is short and appears to be a press release announcing the action, not the detailed regulatory filing itself.
2025-02-28 English
Rättelse: Emission och återköp av C-aktier för aktieägarprogram
Transaction in Own Shares Classification · 1% confidence The document text describes a decision by the Board of Directors to conduct a new issuance (emission) and subsequent repurchase (återköp) of C-shares related to employee incentive programs (LTIPs and SHP). This directly concerns changes to the company's capital structure and share issuance/repurchase activities. The key terms are 'nyemission' (new issuance) and 'återköpa' (repurchase). This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA) or 'Transaction in Own Shares' (POS). Since the primary action described is the issuance and immediate repurchase of shares to fulfill incentive plans, 'Transaction in Own Shares' (POS) is highly specific, but 'Share Issue/Capital Change' (SHA) is also relevant. Given the context of fulfilling incentive programs via issuance and immediate repurchase, POS is the most precise fit for the transaction type described (buying back shares to deliver them). However, the document also explicitly mentions the issuance ('nyemission'). Since the core activity involves both issuance and repurchase related to capital structure management, SHA (Share Issue/Capital Change) is a strong candidate, as is POS (Transaction in Own Shares). Since the text details the mechanics of issuing shares and then immediately buying them back to cover obligations, POS is slightly more descriptive of the specific mechanism used to manage the share pool for the incentive plans. I will classify it as POS, as the repurchase is a central element of the described process.
2025-02-28 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.